董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Orloff | 男 | Director | 68 | 22.69万美元 | 5.11 | 2026-05-11 |
| Hongbo Lu | 女 | Director | 55 | 21.69万美元 | 36.03 | 2026-05-11 |
| Patrick Enright | 男 | Director | 63 | 22.50万美元 | 263.15 | 2026-05-11 |
| Jake Nunn | 男 | Director | 56 | 21.90万美元 | 1.23 | 2026-05-11 |
| Patricia Allen | 女 | Director | 64 | 22.90万美元 | 5.76 | 2026-05-11 |
| James Boylan | 男 | Lead Independent Director | 59 | 24.19万美元 | 393.15 | 2026-05-11 |
| Leon Oliver Moulder | 男 | Chairman and Chief Executive Officer and Director | 69 | 466.10万美元 | 293.85 | 2026-05-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lisa von Moltke | 女 | Chief Medical Officer and Head of Research and Development | 67 | 349.94万美元 | 未持股 | 2026-05-11 |
| Jennifer Fox | 女 | Chief Business Officer and Chief Financial Officer | 55 | 483.53万美元 | 未持股 | 2026-05-11 |
| Joseph L. Farmer | 男 | Chief Operating Officer and President | 54 | 未披露 | 未持股 | 2026-05-11 |
| Lisa von Moltke | 女 | Chief Medical Officer and Head of Research and Development | 67 | 未披露 | 未持股 | 2026-05-11 |
| Joseph L. Farmer | 男 | Chief Operating Officer and President | 54 | 252.65万美元 | 49.21 | 2026-05-11 |
| Leon Oliver Moulder | 男 | Chairman and Chief Executive Officer and Director | 69 | 466.10万美元 | 293.85 | 2026-05-11 |
董事简历
中英对照 | 中文 | 英文- John Orloff
-
John Orloff，自2022年1月起担任Zenas Biopharma, Inc.董事会成员。自2021年10月以来，他一直是Agent Capital LLC（一家医疗风险投资公司）的风险合伙人。在加入Agent Capital之前，他曾担任Alexion Pharmaceuticals Inc.的执行副总裁兼全球研发主管（从2017年6月到2021年7月）。从2015年7月到2016年7月，他还担任Baxalta Inc.的全球研发主管和首席科学官，并在Novelion Therapeutics Inc.、Baxter BioScience、Merck Serono、Novartis AG和Merck Research Laboratories担任执行领导职务。他目前担任上市公司BenevolentAI Ltd. （AMS： BAI）的董事会成员。在制药行业工作之前，他从1990年到1997年担任耶鲁大学医学院的教员。他持有Dartmouth College的化学学士学位，以及the University of Vermont, College of Medicine的医学博士学位。Orloff博士还在耶鲁大学医学院（Yale University School of Medicine）完成了内分泌学和新陈代谢的研究。
John Orloff has served as a member of board of directors since January 2022. Dr. Orloff has been a Venture Partner at Agent Capital LLC ("Agent Capital"), a healthcare venture capital firm, since October 2021. Prior to Agent Capital, Dr. Orloff served as Executive Vice President and Global Head of Research and Development for Alexion Pharmaceuticals Inc. from June 2017 until July 2021. Dr. Orloff also served as Global Head of Research and Development and Chief Scientific Officer at Baxalta Inc. from July 2015 until July 2016, and has held executive leadership roles with Novelion Therapeutics Inc., Baxter BioScience, Merck Serono, Novartis AG and Merck Research Laboratories. Dr. Orloff previoly served on the board of directors of publicly traded BenevolentAI Ltd. (AMS: BAI) from September 2021 until October 2024. Prior to his work in the pharmaceutical indtry, Dr. Orloff was a faculty member at the Yale University School of Medicine from 1990 until 1997. Dr. Orloff holds an undergraduate degree in chemistry from Dartmouth College and earned his M.D. from the University of Vermont, College of Medicine. Dr. Orloff also completed a fellowship in endocrinology and metabolism at Yale University School of Medicine. - John Orloff，自2022年1月起担任Zenas Biopharma, Inc.董事会成员。自2021年10月以来，他一直是Agent Capital LLC（一家医疗风险投资公司）的风险合伙人。在加入Agent Capital之前，他曾担任Alexion Pharmaceuticals Inc.的执行副总裁兼全球研发主管（从2017年6月到2021年7月）。从2015年7月到2016年7月，他还担任Baxalta Inc.的全球研发主管和首席科学官，并在Novelion Therapeutics Inc.、Baxter BioScience、Merck Serono、Novartis AG和Merck Research Laboratories担任执行领导职务。他目前担任上市公司BenevolentAI Ltd. （AMS： BAI）的董事会成员。在制药行业工作之前，他从1990年到1997年担任耶鲁大学医学院的教员。他持有Dartmouth College的化学学士学位，以及the University of Vermont, College of Medicine的医学博士学位。Orloff博士还在耶鲁大学医学院（Yale University School of Medicine）完成了内分泌学和新陈代谢的研究。
- John Orloff has served as a member of board of directors since January 2022. Dr. Orloff has been a Venture Partner at Agent Capital LLC ("Agent Capital"), a healthcare venture capital firm, since October 2021. Prior to Agent Capital, Dr. Orloff served as Executive Vice President and Global Head of Research and Development for Alexion Pharmaceuticals Inc. from June 2017 until July 2021. Dr. Orloff also served as Global Head of Research and Development and Chief Scientific Officer at Baxalta Inc. from July 2015 until July 2016, and has held executive leadership roles with Novelion Therapeutics Inc., Baxter BioScience, Merck Serono, Novartis AG and Merck Research Laboratories. Dr. Orloff previoly served on the board of directors of publicly traded BenevolentAI Ltd. (AMS: BAI) from September 2021 until October 2024. Prior to his work in the pharmaceutical indtry, Dr. Orloff was a faculty member at the Yale University School of Medicine from 1990 until 1997. Dr. Orloff holds an undergraduate degree in chemistry from Dartmouth College and earned his M.D. from the University of Vermont, College of Medicine. Dr. Orloff also completed a fellowship in endocrinology and metabolism at Yale University School of Medicine.
- Hongbo Lu
-
Hongbo Lu自2020年4月以来一直担任我们的董事会成员。她自2021年1月起担任风险投资公司Vivo Capital的管理合伙人。她此前曾于2017年1月至2020年12月担任风险投资公司Lilly Asia Ventures的管理合伙人。2011年6月至2016年10月，她曾担任OrbiMed Advisors LLC的董事总经理。陆博士目前担任几家私人生物技术公司的董事会成员，例如PINS Medical，Inc.，Elpiscience和Geneception。她曾于2017年5月至2019年5月担任上市公司董事会成员，包括上市生物技术公司Turning PointTherapeutics，Inc.，并于2018年5月至2019年2月担任上市生物技术公司Avedro，Inc.的董事会成员。陆博士在中国清华大学获得材料科学与工程本科学位，在华盛顿大学获得生物工程博士学位，在加州大学伯克利分校获得工商管理硕士学位。
Hongbo Lu has served as a member of board of directors since November 2022. Dr. Lu is the Managing Member of NEXTBio Capital, a biotech investment firm. Dr. Lu. was previoly a Managing Partner at Vivo Capital LLC from December 2020 until January 2024. Previoly, Dr. Lu served as a Managing Partner at Lilly Asia Ventures from January 2017 until December 2020 ("LAV"). Prior to her role at LAV, she was affiliated with OrbiMed Advisors from June 2011 until October 2016, lastly as its Managing Director. Dr. Lu previoly served on the boards of directors of public companies including Turning Point Therapeutics, Inc. (Nasdaq: TPTX, acquired by Bristol Myers Squibb), Crown Bioscience Inc. (6554.TT, acquired by JSR), Avedro Inc. (Nasdaq: AVDR, acquired by Glaukos) and Terns Pharmaceuticals Inc. (Nasdaq: TERN, from April 2020 until Augt 2025). She currently serves on the board of Arrowhead Pharmaceuticals (Nasdaq: ARWR, since March 2024). Dr. Lu started her Wall Street career as a biotech analyst at Piper Jaffray & Co. and was previoly involved in biotech start up Zyomyx in the San Francisco Bay Area. Dr. Lu earned a Ph.D. in Bioengineering from the University of Washington, an M.B.A. from the Haas School of Biness at the University of California, Berkeley, and graduated with honors from Tsinghua University. - Hongbo Lu自2020年4月以来一直担任我们的董事会成员。她自2021年1月起担任风险投资公司Vivo Capital的管理合伙人。她此前曾于2017年1月至2020年12月担任风险投资公司Lilly Asia Ventures的管理合伙人。2011年6月至2016年10月，她曾担任OrbiMed Advisors LLC的董事总经理。陆博士目前担任几家私人生物技术公司的董事会成员，例如PINS Medical，Inc.，Elpiscience和Geneception。她曾于2017年5月至2019年5月担任上市公司董事会成员，包括上市生物技术公司Turning PointTherapeutics，Inc.，并于2018年5月至2019年2月担任上市生物技术公司Avedro，Inc.的董事会成员。陆博士在中国清华大学获得材料科学与工程本科学位，在华盛顿大学获得生物工程博士学位，在加州大学伯克利分校获得工商管理硕士学位。
- Hongbo Lu has served as a member of board of directors since November 2022. Dr. Lu is the Managing Member of NEXTBio Capital, a biotech investment firm. Dr. Lu. was previoly a Managing Partner at Vivo Capital LLC from December 2020 until January 2024. Previoly, Dr. Lu served as a Managing Partner at Lilly Asia Ventures from January 2017 until December 2020 ("LAV"). Prior to her role at LAV, she was affiliated with OrbiMed Advisors from June 2011 until October 2016, lastly as its Managing Director. Dr. Lu previoly served on the boards of directors of public companies including Turning Point Therapeutics, Inc. (Nasdaq: TPTX, acquired by Bristol Myers Squibb), Crown Bioscience Inc. (6554.TT, acquired by JSR), Avedro Inc. (Nasdaq: AVDR, acquired by Glaukos) and Terns Pharmaceuticals Inc. (Nasdaq: TERN, from April 2020 until Augt 2025). She currently serves on the board of Arrowhead Pharmaceuticals (Nasdaq: ARWR, since March 2024). Dr. Lu started her Wall Street career as a biotech analyst at Piper Jaffray & Co. and was previoly involved in biotech start up Zyomyx in the San Francisco Bay Area. Dr. Lu earned a Ph.D. in Bioengineering from the University of Washington, an M.B.A. from the Haas School of Biness at the University of California, Berkeley, and graduated with honors from Tsinghua University.
- Patrick Enright
-
Patrick Enright自2015年7月以来一直担任我们的董事会成员。Enright自2006年1月起担任Longitude Capital Management（一家梦百合风险投资公司）总经理。恩赖特先生目前担任临床阶段生物制药公司Aimmune治疗公司、临床阶段制药公司AptinyxInc.和制药公司Jazz Pharmaceuticals plc的董事会成员，以及私营生命科学公司的董事会成员。Enright先生拥有斯坦福大学（Stanford University）生物科学学士学位和宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）工商管理硕士学位。
Patrick Enright has served as a member of VeraDermics, Incorporated board of directors since December 2024. Mr. Enright has served as a Managing Director of Longitude Capital Management Co., LLC, a healthcare venture capital firm co founded by Mr. Enright, since 2006. Previously, Mr. Enright was a Managing Director of Pequot Ventures, a venture capital firm, where he co led the life sciences investment practice, and served in various senior executive positions at Valentis Inc., Boehringer Mannheim Pharmaceuticals Corp. and Sandoz Inc. Mr. Enright is currently a member of the board of directors of BioAge Labs, Inc., Jazz Pharmaceuticals PLC, Vera Therapeutics, Inc. and Zenas BioPharma, Inc., and has served on such boards since February 2024, January 2012, October 2020 and November 2022, respectively. Mr. Enright also served on the board of directors of Aptinyx Inc. from March 2016 to December 2022. Mr. Enright received his B.S. in Biological Sciences from Stanford University and his M.B.A. from the Wharton School of the University of Pennsylvania. - Patrick Enright自2015年7月以来一直担任我们的董事会成员。Enright自2006年1月起担任Longitude Capital Management（一家梦百合风险投资公司）总经理。恩赖特先生目前担任临床阶段生物制药公司Aimmune治疗公司、临床阶段制药公司AptinyxInc.和制药公司Jazz Pharmaceuticals plc的董事会成员，以及私营生命科学公司的董事会成员。Enright先生拥有斯坦福大学（Stanford University）生物科学学士学位和宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）工商管理硕士学位。
- Patrick Enright has served as a member of VeraDermics, Incorporated board of directors since December 2024. Mr. Enright has served as a Managing Director of Longitude Capital Management Co., LLC, a healthcare venture capital firm co founded by Mr. Enright, since 2006. Previously, Mr. Enright was a Managing Director of Pequot Ventures, a venture capital firm, where he co led the life sciences investment practice, and served in various senior executive positions at Valentis Inc., Boehringer Mannheim Pharmaceuticals Corp. and Sandoz Inc. Mr. Enright is currently a member of the board of directors of BioAge Labs, Inc., Jazz Pharmaceuticals PLC, Vera Therapeutics, Inc. and Zenas BioPharma, Inc., and has served on such boards since February 2024, January 2012, October 2020 and November 2022, respectively. Mr. Enright also served on the board of directors of Aptinyx Inc. from March 2016 to December 2022. Mr. Enright received his B.S. in Biological Sciences from Stanford University and his M.B.A. from the Wharton School of the University of Pennsylvania.
- Jake Nunn
-
Jake Nunn在生命科学行业拥有超过25年的经验，担任投资者、独立董事、研究分析师和投资银行家。杰克目前是New Enterprise Associates（NEA）的风险顾问，2006年至2018年担任合伙人，专注于后期专业制药，生物技术和医疗设备投资，并管理NEA在梦百合的多项公共投资。Jake是Oventus Medical Ltd.董事。ASX:OVN，Regulus Therapeutics（NASDAQ:RGLS）和Trevena，Inc.（NASDAQ:TRVN）。他此前曾担任Dermira Inc.（被Eli Lilly公司收购）、Hyperion Therapeutics公司（被Horizon Pharma plc公司收购）、TriVascular公司（被Endologix公司收购）、Aciex Therapeutics公司（被Nicox SA公司收购）、Transcept Pharmaceuticals公司（与Paratek公司合并）的董事，以及Vertiflex，Inc.（被Boston Scientific公司收购）的董事会观察员。任职NEA公司之前，他曾任职MPM Capital公司，担任MPM BioEquities Fund的合伙人，在那里他专注于公共、管道和夹层阶段的生命科学投资。此前，他是富兰克林邓普顿投资公司（Franklin Templeton Investments）的梦百合研究分析师和投资组合经理。杰克也是Alex.Brown&Sons的投资银行家。他在斯坦福商学院（Stanford Graduate School of Business）获得工商管理硕士学位，在达特茅斯学院（Dartmouth College）获得经济学AB学位。Jake持有特许金融分析师称号，是旧金山CFA Society of San Francisco成员，最近完成Stanford GSB Directors’Consortium高管教育计划。
Jake Nunn has more than 30 years of experience in the life science industry as an investor, independent director, research analyst and investment banker. He is currently an independent advisor to life science companies and a partner at SR One Capital Management. Mr. Nunn was previously a venture advisor at New Enterprise Associates, or NEA, where he was a partner from 2006 to 2018, focusing on later stage specialty pharmaceuticals, biotechnology and medical device investments and managing a number of NEA's public investments in healthcare. Mr. Nunn is a Director of Zenas BioPharma, Inc. (Nasdaq: ZBIO). He previously was a Director of Regulus Therapeutics (acquired by Novartis),Dermira Inc. (acquired by Eli Lilly), Hyperion Therapeutics (acquired by Horizon Pharma PLC), TriVascular (acquired by Endologix), Aciex Therapeutics (acquired by Nicox SA), Transcept Pharmaceuticals (merged with Paratek) and a board observer at Vertiflex, Inc. (acquired by Boston Scientific). Prior to NEA, Mr. Nunn worked at MPM Capital as a Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine stage life sciences investing. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments. Mr. Nunn was also an investment banker with Alex. Brown & Sons. He received an MBA from the Stanford Graduate School of Business and an AB in Economics from Dartmouth College. Mr. Nunn holds the Chartered Financial Analyst designation, is a member of the CFA Society of San Francisco, and recently completed the Stanford GSB Directors' Consortium executive education program. - Jake Nunn在生命科学行业拥有超过25年的经验，担任投资者、独立董事、研究分析师和投资银行家。杰克目前是New Enterprise Associates（NEA）的风险顾问，2006年至2018年担任合伙人，专注于后期专业制药，生物技术和医疗设备投资，并管理NEA在梦百合的多项公共投资。Jake是Oventus Medical Ltd.董事。ASX:OVN，Regulus Therapeutics（NASDAQ:RGLS）和Trevena，Inc.（NASDAQ:TRVN）。他此前曾担任Dermira Inc.（被Eli Lilly公司收购）、Hyperion Therapeutics公司（被Horizon Pharma plc公司收购）、TriVascular公司（被Endologix公司收购）、Aciex Therapeutics公司（被Nicox SA公司收购）、Transcept Pharmaceuticals公司（与Paratek公司合并）的董事，以及Vertiflex，Inc.（被Boston Scientific公司收购）的董事会观察员。任职NEA公司之前，他曾任职MPM Capital公司，担任MPM BioEquities Fund的合伙人，在那里他专注于公共、管道和夹层阶段的生命科学投资。此前，他是富兰克林邓普顿投资公司（Franklin Templeton Investments）的梦百合研究分析师和投资组合经理。杰克也是Alex.Brown&Sons的投资银行家。他在斯坦福商学院（Stanford Graduate School of Business）获得工商管理硕士学位，在达特茅斯学院（Dartmouth College）获得经济学AB学位。Jake持有特许金融分析师称号，是旧金山CFA Society of San Francisco成员，最近完成Stanford GSB Directors’Consortium高管教育计划。
- Jake Nunn has more than 30 years of experience in the life science industry as an investor, independent director, research analyst and investment banker. He is currently an independent advisor to life science companies and a partner at SR One Capital Management. Mr. Nunn was previously a venture advisor at New Enterprise Associates, or NEA, where he was a partner from 2006 to 2018, focusing on later stage specialty pharmaceuticals, biotechnology and medical device investments and managing a number of NEA's public investments in healthcare. Mr. Nunn is a Director of Zenas BioPharma, Inc. (Nasdaq: ZBIO). He previously was a Director of Regulus Therapeutics (acquired by Novartis),Dermira Inc. (acquired by Eli Lilly), Hyperion Therapeutics (acquired by Horizon Pharma PLC), TriVascular (acquired by Endologix), Aciex Therapeutics (acquired by Nicox SA), Transcept Pharmaceuticals (merged with Paratek) and a board observer at Vertiflex, Inc. (acquired by Boston Scientific). Prior to NEA, Mr. Nunn worked at MPM Capital as a Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine stage life sciences investing. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments. Mr. Nunn was also an investment banker with Alex. Brown & Sons. He received an MBA from the Stanford Graduate School of Business and an AB in Economics from Dartmouth College. Mr. Nunn holds the Chartered Financial Analyst designation, is a member of the CFA Society of San Francisco, and recently completed the Stanford GSB Directors' Consortium executive education program.
- Patricia Allen
-
Patricia Allen，于2021年3月至2024年1月担任拜耳全资且独立运营的子公司Vividion Therapeutics, Inc.的首席财务官。2013年1月至2020年5月，Allen女士担任Zafgen，Inc.（现为Larimar治疗公司）的首席财务官。此前，2004年至2011年，Allen女士担任上市生物技术公司Alnylam Pharmaceuticals, Inc.的财务副总裁、财务主管和首席财务官。在加入Alnylam之前，Allen女士任职于Alkermes, Inc.，一家上市的生物技术公司，最近担任财务总监。她自2016年9月起担任Deciphera Pharmaceuticals, Inc.（纳斯达克：DCPH）的董事会成员，并于2019年8月至2022年12月完成合并期间担任生物技术上市公司Yumanity Therapeutics, Inc.的董事会成员。艾伦女士的职业生涯始于德勤会计师事务所（Deloitte & Touche，LLP）的审计师。艾伦女士以优异成绩毕业于布莱恩特学院，获得工商管理学士学位。
Patricia Allen has been a member of board of directors since February 2024. Ms. Allen served as the Chief Financial Officer of Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer, from March 2021 until January 2024. From January 2013 to May 2020, Ms. Allen served as Chief Financial Officer of Zafgen, Inc., now Larimar Therapeutics Inc. Previoly, from 2004 to 2011, Ms. Allen served as the Vice President of Finance, Treasurer, and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., a publicly traded biotechnology company. Prior to Alnylam, Ms. Allen was at Alkermes, Inc., a publicly traded biotechnology company, most recently as the Director of Finance. She served on the board of directors of Deciphera Pharmaceuticals, Inc. (Nasdaq: DCPH), a publicly traded biotechnology company, from September 2016 until its acquisition by ONO Pharmaceutical in June 2024, and Yumanity Therapeutics, Inc., a publicly traded biotechnology company, from Augt 2019 until the completion of its merger in December 2022. Ms. Allen began her career as an auditor at Deloitte & Touche, LLP. Ms. Allen graduated summa cum laude from Bryant College with a B.S. in biness administration. - Patricia Allen，于2021年3月至2024年1月担任拜耳全资且独立运营的子公司Vividion Therapeutics, Inc.的首席财务官。2013年1月至2020年5月，Allen女士担任Zafgen，Inc.（现为Larimar治疗公司）的首席财务官。此前，2004年至2011年，Allen女士担任上市生物技术公司Alnylam Pharmaceuticals, Inc.的财务副总裁、财务主管和首席财务官。在加入Alnylam之前，Allen女士任职于Alkermes, Inc.，一家上市的生物技术公司，最近担任财务总监。她自2016年9月起担任Deciphera Pharmaceuticals, Inc.（纳斯达克：DCPH）的董事会成员，并于2019年8月至2022年12月完成合并期间担任生物技术上市公司Yumanity Therapeutics, Inc.的董事会成员。艾伦女士的职业生涯始于德勤会计师事务所（Deloitte & Touche，LLP）的审计师。艾伦女士以优异成绩毕业于布莱恩特学院，获得工商管理学士学位。
- Patricia Allen has been a member of board of directors since February 2024. Ms. Allen served as the Chief Financial Officer of Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer, from March 2021 until January 2024. From January 2013 to May 2020, Ms. Allen served as Chief Financial Officer of Zafgen, Inc., now Larimar Therapeutics Inc. Previoly, from 2004 to 2011, Ms. Allen served as the Vice President of Finance, Treasurer, and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., a publicly traded biotechnology company. Prior to Alnylam, Ms. Allen was at Alkermes, Inc., a publicly traded biotechnology company, most recently as the Director of Finance. She served on the board of directors of Deciphera Pharmaceuticals, Inc. (Nasdaq: DCPH), a publicly traded biotechnology company, from September 2016 until its acquisition by ONO Pharmaceutical in June 2024, and Yumanity Therapeutics, Inc., a publicly traded biotechnology company, from Augt 2019 until the completion of its merger in December 2022. Ms. Allen began her career as an auditor at Deloitte & Touche, LLP. Ms. Allen graduated summa cum laude from Bryant College with a B.S. in biness administration.
- James Boylan
-
James Boylan，自2022年5月起担任Patient Square Capital旗下投资组合公司Enavate Sciences Inc.的首席执行官。在此之前，Boylan先生曾担任SVB Leerink的总裁兼投资银行业务主管，在那里他构建并领导了Leerink Swann向行业领先的医疗保健投资银行的转型，该投资银行于2019年被硅谷银行收购。在SVB Leerink的12年以及之前在美林证券担任董事总经理的12年期间，博伊兰先生与数百家生命科学和生物技术公司合作，制定战略并在资本市场和并购中完成交易。Boylan先生还在CAMP4 Therapeutics Corp.、Compass Therapeutics, Inc.和Immunome, Inc.的董事会任职。Boylan先生拥有哥伦比亚大学商学院的金融工商管理硕士学位和利哈伊大学的金融学士学位。
James Boylan has served as a member of board of directors since November 2022. Mr. Boylan has served as Chief Executive Officer of Enavate Sciences Inc., a portfolio company of Patient Square Capital, since May 2022. Mr. Boylan currently serves on the board of directors of Immunome Therapeutics Inc. (Nasdaq: IMNM), Compass Therapeutics, Inc. (Nasdaq: CMPX) and Graviton Biosciences. Previoly, Mr. Boylan served on the board of directors of CAMP4 Therapeutics Corp. (Nasdaq: CAMP). Prior to Enavate Sciences, Mr. Boylan was the President and Head of Investment Banking of SVB Leerink and Managing Director, Healthcare Investment Banking at Merrill Lynch and Company. Across his 25 years in investment banking, Mr. Boylan has worked with hundreds of life sciences and biotechnology companies to develop strategy and complete transactions in capital markets and mergers & acquisitions. Mr. Boylan earned an M.B.A. in finance from the Columbia Biness School and a B.S. in finance from Lehigh University. - James Boylan，自2022年5月起担任Patient Square Capital旗下投资组合公司Enavate Sciences Inc.的首席执行官。在此之前，Boylan先生曾担任SVB Leerink的总裁兼投资银行业务主管，在那里他构建并领导了Leerink Swann向行业领先的医疗保健投资银行的转型，该投资银行于2019年被硅谷银行收购。在SVB Leerink的12年以及之前在美林证券担任董事总经理的12年期间，博伊兰先生与数百家生命科学和生物技术公司合作，制定战略并在资本市场和并购中完成交易。Boylan先生还在CAMP4 Therapeutics Corp.、Compass Therapeutics, Inc.和Immunome, Inc.的董事会任职。Boylan先生拥有哥伦比亚大学商学院的金融工商管理硕士学位和利哈伊大学的金融学士学位。
- James Boylan has served as a member of board of directors since November 2022. Mr. Boylan has served as Chief Executive Officer of Enavate Sciences Inc., a portfolio company of Patient Square Capital, since May 2022. Mr. Boylan currently serves on the board of directors of Immunome Therapeutics Inc. (Nasdaq: IMNM), Compass Therapeutics, Inc. (Nasdaq: CMPX) and Graviton Biosciences. Previoly, Mr. Boylan served on the board of directors of CAMP4 Therapeutics Corp. (Nasdaq: CAMP). Prior to Enavate Sciences, Mr. Boylan was the President and Head of Investment Banking of SVB Leerink and Managing Director, Healthcare Investment Banking at Merrill Lynch and Company. Across his 25 years in investment banking, Mr. Boylan has worked with hundreds of life sciences and biotechnology companies to develop strategy and complete transactions in capital markets and mergers & acquisitions. Mr. Boylan earned an M.B.A. in finance from the Columbia Biness School and a B.S. in finance from Lehigh University.
- Leon Oliver Moulder
-
Leon Oliver Moulder， Zenas Biopharma, Inc.。创始人，曾担任Zenas Biopharma, Inc.自2023年8月起担任Zenas Biopharma, Inc.的首席执行官。自2020年起担任Zenas Biopharma, Inc.的董事长和董事会成员。自2019年3月以来，他还担任早期生命科学投资基金Tellus BioVentures, LLC（“Tellus”）的管理成员。在成立Tellus之前，他共同创立了TESARO，一家总部位于波士顿的完全整合的肿瘤学生物制药公司（“TESARO”），并从2010年3月起担任首席执行官兼董事，直到2019年1月被GlaxoSmithKline收购。2009年至2010年，他曾担任Abraxis BioScience Inc.（“Abraxis”）的总裁、首席执行官和副董事长。在Abraxis之前，他曾在卫材收购MGI PHARMA后担任北美卫材公司的副董事长，在那里他担任总裁兼首席执行官。此前，他曾担任Eligix Inc.（风险阶段生物技术公司）的创始管理团队成员。他的职业生涯始于临床药剂师，随后在Sanofi S.A.（纳斯达克股票代码：SNY）的前身公司（从Marion Laboratories Inc.开始）工作了17年。Moulder先生是天普大学董事和天普大学日本分校主席。他是芝加哥大学布斯商学院和波尔斯基创业与创新中心的理事会成员。Moulder先生担任Zai Lab Ltd.（纳斯达克股票代码：ZLAB）（“Zai Lab”）、赫尔辛基集团和Trevena Inc.（纳斯达克股票代码：TRVN）以及几家Tellus投资组合公司的董事会成员，包括Dianthus（纳斯达克股票代码：DNTH）。Moulder先生拥有天普大学（Temple University）的药学学位和芝加哥大学布斯商学院（The University of Chicago Booth School of Business）的工商管理硕士学位。于2020年12月担任再鼎医药有限公司提名及企业管治委员会主席。于2026年03月05日调任为再鼎医药有限公司董事。
Leon Oliver Moulder is Founder, has served as Chief Executive Officer since August 2023, and as Chairman and a member of the board of directors since 2020. He has also been the Managing Member of Tell BioVentures, LLC ("Tell"), an early stage life sciences investment fund, since March 2019. Prior to establishing Tell, he cofounded TESARO, Inc., a fully integrated Boston based oncology focused biopharmaceutical company, and served as Chief Executive Officer and director from March 2010 until its acquisition by GlaxoSmithKline in January 2019. Mr. Moulder previoly served as President, Chief Executive Officer and Vice Chairman of Abraxis BioScience Inc. from 2009 to 2010. Prior to Abraxis, he served as Vice Chairman of Eisai Corporation of North America following Eisai's acquisition of MGI PHARMA, where he served as President and Chief Executive Officer. This follod him serving as a member of the founding management team of a venture stage biotech company. Mr. Moulder began his career as a clinical pharmacist follod by a 17 year career at predecessor companies of Sanofi S.A. (Nasdaq: SNY), beginning with Marion Laboratories Inc. Mr. Moulder is a Temple University Trtee and Chair of Temple University Japan. He is a Council Member for both the University of Chicago Booth School of Biness and the Polsky Center for Entrepreneurship and Innovation. Mr. Moulder currently serves on the board of directors of Zai Lab Ltd. (Nasdaq: ZLAB) ("Zai Lab") and for several Tell BioVentures private portfolio companies. Mr. Moulder previoly served on the board of directors of Trevena, Inc. (Nasdaq: TRVN) from 2013 until 2023 and Dianth (Nasdaq: DNTH) from 2019 until 2025. Mr. Moulder received a Pharmacy degree from Temple University and an M.B.A. from The University of Chicago Booth School of Biness. - Leon Oliver Moulder， Zenas Biopharma, Inc.。创始人，曾担任Zenas Biopharma, Inc.自2023年8月起担任Zenas Biopharma, Inc.的首席执行官。自2020年起担任Zenas Biopharma, Inc.的董事长和董事会成员。自2019年3月以来，他还担任早期生命科学投资基金Tellus BioVentures, LLC（“Tellus”）的管理成员。在成立Tellus之前，他共同创立了TESARO，一家总部位于波士顿的完全整合的肿瘤学生物制药公司（“TESARO”），并从2010年3月起担任首席执行官兼董事，直到2019年1月被GlaxoSmithKline收购。2009年至2010年，他曾担任Abraxis BioScience Inc.（“Abraxis”）的总裁、首席执行官和副董事长。在Abraxis之前，他曾在卫材收购MGI PHARMA后担任北美卫材公司的副董事长，在那里他担任总裁兼首席执行官。此前，他曾担任Eligix Inc.（风险阶段生物技术公司）的创始管理团队成员。他的职业生涯始于临床药剂师，随后在Sanofi S.A.（纳斯达克股票代码：SNY）的前身公司（从Marion Laboratories Inc.开始）工作了17年。Moulder先生是天普大学董事和天普大学日本分校主席。他是芝加哥大学布斯商学院和波尔斯基创业与创新中心的理事会成员。Moulder先生担任Zai Lab Ltd.（纳斯达克股票代码：ZLAB）（“Zai Lab”）、赫尔辛基集团和Trevena Inc.（纳斯达克股票代码：TRVN）以及几家Tellus投资组合公司的董事会成员，包括Dianthus（纳斯达克股票代码：DNTH）。Moulder先生拥有天普大学（Temple University）的药学学位和芝加哥大学布斯商学院（The University of Chicago Booth School of Business）的工商管理硕士学位。于2020年12月担任再鼎医药有限公司提名及企业管治委员会主席。于2026年03月05日调任为再鼎医药有限公司董事。
- Leon Oliver Moulder is Founder, has served as Chief Executive Officer since August 2023, and as Chairman and a member of the board of directors since 2020. He has also been the Managing Member of Tell BioVentures, LLC ("Tell"), an early stage life sciences investment fund, since March 2019. Prior to establishing Tell, he cofounded TESARO, Inc., a fully integrated Boston based oncology focused biopharmaceutical company, and served as Chief Executive Officer and director from March 2010 until its acquisition by GlaxoSmithKline in January 2019. Mr. Moulder previoly served as President, Chief Executive Officer and Vice Chairman of Abraxis BioScience Inc. from 2009 to 2010. Prior to Abraxis, he served as Vice Chairman of Eisai Corporation of North America following Eisai's acquisition of MGI PHARMA, where he served as President and Chief Executive Officer. This follod him serving as a member of the founding management team of a venture stage biotech company. Mr. Moulder began his career as a clinical pharmacist follod by a 17 year career at predecessor companies of Sanofi S.A. (Nasdaq: SNY), beginning with Marion Laboratories Inc. Mr. Moulder is a Temple University Trtee and Chair of Temple University Japan. He is a Council Member for both the University of Chicago Booth School of Biness and the Polsky Center for Entrepreneurship and Innovation. Mr. Moulder currently serves on the board of directors of Zai Lab Ltd. (Nasdaq: ZLAB) ("Zai Lab") and for several Tell BioVentures private portfolio companies. Mr. Moulder previoly served on the board of directors of Trevena, Inc. (Nasdaq: TRVN) from 2013 until 2023 and Dianth (Nasdaq: DNTH) from 2019 until 2025. Mr. Moulder received a Pharmacy degree from Temple University and an M.B.A. from The University of Chicago Booth School of Biness.
高管简历
中英对照 | 中文 | 英文- Lisa von Moltke
Lisa von Moltke自2020年3月起担任我们的执行Vice President兼首席医疗官。此前，Von Moltke博士自2015年6月起在制药公司Alkermes，Inc.工作，担任高级职位，最终于2015年6月至2019年12月担任高级副总裁兼临床开发主管。从2015年6月开始，Moltke博士担任临床药理学，DMPK和生物分析副总裁，于2015年11月晋升为临床开发主管，并于2018年6月成为高级副总裁。在加入Alkermes之前，Von Moltke博士于2009年至2015年担任赛诺菲/健赞公司（一家生物技术公司）临床药理学Vice President，并担任美国临床与探索药理学科学CEP和早期开发主管。从2014年开始，她担任CEP的日本和中国地区主管。Von Moltke从2006年到2009年担任Takeda Oncology Company（马萨诸塞州剑桥市一家生物制药公司）转化医学主管。她曾担任the American College of Clinical Pharmacology的总裁，以及the Journal of Clinical Pharmacology的主编。Von Moltke博士在Wellesley College获得文学学士学位，并在Michigan State University人类医学院获得医学博士学位。
Lisa von Moltke has served as our Executive Vice President and Chief Medical Officer since March 2020. Previously, Dr. von Moltke worked for Alkermes, Inc., a pharmaceutical company, from June 2015 to December 2019 where she served in roles of increasing seniority, culminating as Senior Vice President and Head of Clinical Development. Beginning in June 2015 Dr. Moltke served as VP Clinical Pharmacology, DMPK and Bioanalytics, was promoted to Head of Clinical Development in November 2015 and became SVP in June 2018. Prior to joining Alkermes, Dr. von Moltke served as Vice President Clinical Pharmacology at Sanofi/Genzyme Corporation, a biotechnology company, from 2009 to 2015 and was US Head Clinical & Exploratory Pharmacology Sciences CEP and Early Development. Starting in 2014 she was Head CEP for Japan and China regions. From 2006 to 2009 Dr. von Moltke was Head, Translational Medicine for the Takeda Oncology Company, a biopharmaceutical company, in Cambridge, MA. She has served as President of the American College of Clinical Pharmacology, and as the Editor-in-Chief of The Journal of Clinical Pharmacology. Dr. von Moltke earned a B.A. degree at Wellesley College and her M.D. from Michigan State University, College of Human Medicine.- Lisa von Moltke自2020年3月起担任我们的执行Vice President兼首席医疗官。此前，Von Moltke博士自2015年6月起在制药公司Alkermes，Inc.工作，担任高级职位，最终于2015年6月至2019年12月担任高级副总裁兼临床开发主管。从2015年6月开始，Moltke博士担任临床药理学，DMPK和生物分析副总裁，于2015年11月晋升为临床开发主管，并于2018年6月成为高级副总裁。在加入Alkermes之前，Von Moltke博士于2009年至2015年担任赛诺菲/健赞公司（一家生物技术公司）临床药理学Vice President，并担任美国临床与探索药理学科学CEP和早期开发主管。从2014年开始，她担任CEP的日本和中国地区主管。Von Moltke从2006年到2009年担任Takeda Oncology Company（马萨诸塞州剑桥市一家生物制药公司）转化医学主管。她曾担任the American College of Clinical Pharmacology的总裁，以及the Journal of Clinical Pharmacology的主编。Von Moltke博士在Wellesley College获得文学学士学位，并在Michigan State University人类医学院获得医学博士学位。
- Lisa von Moltke has served as our Executive Vice President and Chief Medical Officer since March 2020. Previously, Dr. von Moltke worked for Alkermes, Inc., a pharmaceutical company, from June 2015 to December 2019 where she served in roles of increasing seniority, culminating as Senior Vice President and Head of Clinical Development. Beginning in June 2015 Dr. Moltke served as VP Clinical Pharmacology, DMPK and Bioanalytics, was promoted to Head of Clinical Development in November 2015 and became SVP in June 2018. Prior to joining Alkermes, Dr. von Moltke served as Vice President Clinical Pharmacology at Sanofi/Genzyme Corporation, a biotechnology company, from 2009 to 2015 and was US Head Clinical & Exploratory Pharmacology Sciences CEP and Early Development. Starting in 2014 she was Head CEP for Japan and China regions. From 2006 to 2009 Dr. von Moltke was Head, Translational Medicine for the Takeda Oncology Company, a biopharmaceutical company, in Cambridge, MA. She has served as President of the American College of Clinical Pharmacology, and as the Editor-in-Chief of The Journal of Clinical Pharmacology. Dr. von Moltke earned a B.A. degree at Wellesley College and her M.D. from Michigan State University, College of Human Medicine.
- Jennifer Fox
詹妮弗·福克斯，自2022年7月以来一直在董事会和全科医生董事会任职。Fox女士自2020年10月起担任Nuvation Bio公司首席财务官。在担任这一职务之前，Fox女士曾于2015年6月至2020年10月担任花旗集团董事总经理兼北美医疗保健企业和投资银行部门联席主管。2006年2月至2015年6月，Fox女士担任德意志银行董事总经理，最近还担任生命科学投资银行集团联席主管。在此之前，福克斯女士曾担任贝尔斯登医疗投资银行高级董事总经理、美国银行医疗投资银行副总裁、金融分析师、投资银行分析师、保诚矢量医疗集团和保诚证券公司医疗投资银行助理、副总裁。福克斯女士在曼哈顿学院获得了金融和市场营销学士学位。
Jennifer Fox has served as Chief Biness Officer and Chief Financial Officer Since December 2023. Previoly, Ms. Fox served as Chief Financial Officer at Nuvation Bio, Inc. (NYSE: NUVB), an oncology foced biopharmaceutical company, from October 2020 until December 2023. Prior to this role, Ms. Fox served as Managing Director, Co Head of North America Healthcare Corporate and Investment Banking Group at Citigroup from June 2015 to October 2020. From February 2006 to June 2015, Ms. Fox served as Managing Director at Deutsche Bank, and most recently also as Co Head of Life Sciences Investment Banking Group. Prior to that, Ms. Fox served as Senior Managing Director Healthcare Investment Banking at Bear Stearns, Vice President Healthcare Investment Banking at Bank of America and Financial Analyst, Investment Banking Analyst, Associate, Vice President, Health Care Investment Banking at Prudential Vector Healthcare Group and Prudential Securities Incorporated. Ms. Fox serves on the board of directors for Apogee Therapeutics (Nasdaq: APGE), ProKidney Corp. (Nasdaq: PROK) and Life Science Cares. She has more than 25 years of experience in healthcare investment banking and has been a lead adviser to life science companies on over 125 financing and strategic transactions. Ms. Fox received B.S. degrees in Finance and Marketing from Manhattan College.- 詹妮弗·福克斯，自2022年7月以来一直在董事会和全科医生董事会任职。Fox女士自2020年10月起担任Nuvation Bio公司首席财务官。在担任这一职务之前，Fox女士曾于2015年6月至2020年10月担任花旗集团董事总经理兼北美医疗保健企业和投资银行部门联席主管。2006年2月至2015年6月，Fox女士担任德意志银行董事总经理，最近还担任生命科学投资银行集团联席主管。在此之前，福克斯女士曾担任贝尔斯登医疗投资银行高级董事总经理、美国银行医疗投资银行副总裁、金融分析师、投资银行分析师、保诚矢量医疗集团和保诚证券公司医疗投资银行助理、副总裁。福克斯女士在曼哈顿学院获得了金融和市场营销学士学位。
- Jennifer Fox has served as Chief Biness Officer and Chief Financial Officer Since December 2023. Previoly, Ms. Fox served as Chief Financial Officer at Nuvation Bio, Inc. (NYSE: NUVB), an oncology foced biopharmaceutical company, from October 2020 until December 2023. Prior to this role, Ms. Fox served as Managing Director, Co Head of North America Healthcare Corporate and Investment Banking Group at Citigroup from June 2015 to October 2020. From February 2006 to June 2015, Ms. Fox served as Managing Director at Deutsche Bank, and most recently also as Co Head of Life Sciences Investment Banking Group. Prior to that, Ms. Fox served as Senior Managing Director Healthcare Investment Banking at Bear Stearns, Vice President Healthcare Investment Banking at Bank of America and Financial Analyst, Investment Banking Analyst, Associate, Vice President, Health Care Investment Banking at Prudential Vector Healthcare Group and Prudential Securities Incorporated. Ms. Fox serves on the board of directors for Apogee Therapeutics (Nasdaq: APGE), ProKidney Corp. (Nasdaq: PROK) and Life Science Cares. She has more than 25 years of experience in healthcare investment banking and has been a lead adviser to life science companies on over 125 financing and strategic transactions. Ms. Fox received B.S. degrees in Finance and Marketing from Manhattan College.
- Joseph L. Farmer
Joseph Farmer是一位经验丰富的生物制药高管，拥有超过25年的交易和运营经验，曾在从发现到商业化的所有发展阶段与新兴生物技术公司合作。在加入Zenas之前，他曾在免疫肿瘤学公司Xilio Therapeutics, Inc.（纳斯达克：XLO）担任首席运营官，从2019年5月至2021年3月，他领导一般和行政、业务发展以及业务运营职能。在加入Xilio Therapeutics之前，他是TESARO的总法律顾问和公司秘书，领导全球法律、合规和政府事务职能，并且从2015年到2019年1月被葛兰素史克收购，是领导团队的关键成员。他此前曾在Cubist Pharmaceuticals Inc.担任首席公司法律顾问，自2012年起直至2015年被默沙东公司收购，并在两家上市公司担任总法律顾问，其中包括Amag制药公司，他还曾担任该公司的首席行政官。他的职业生涯始于Testa，Hurwitz & Thibeault，LLP的公司律师。法默先生在波士顿学院法学院获得法学博士学位，在波士顿大学获得经济学学士学位。
Joseph L. Farmer has served as President and Chief Operating Officer since February 2022, and served as Chief Biness and Administrative Officer from April 2021 to February 2022. Mr. Farmer is an experienced biopharma executive with over 30 years of transactional and operational experience working with emerging biotechnology companies at all stages of development, from discovery through commercialization. Prior to joining Zenas, he served as Chief Operating Officer at Xilio Therapeutics, Inc. (Nasdaq: XLO), an immuno oncology company, where he led the general and administrative, biness development, and biness operations functions from May 2019 until March 2021. Prior to Xilio Therapeutics, he was the General Counsel and Corporate Secretary at TESARO, a publicly traded biotechnology company, where he led the global legal, compliance and government affairs functions and was a key member of the leadership team from 2015 through its acquisition by GlaxoSmithKline in January 2019. He previoly served as Chief Corporate Counsel at Cubist Pharmaceuticals Inc., from 2012 through its acquisition by Merck & Co. in 2015, and as General Counsel at two publicly traded companies, including AMAG Pharmaceuticals Inc., where he was also the Chief Administrative Officer. He began his career as a corporate attorney at Testa, Hurwitz & Thibeault, LLP. Mr. Farmer received his J.D. from Boston College Law School and his B.A. in economics from Boston University.- Joseph Farmer是一位经验丰富的生物制药高管，拥有超过25年的交易和运营经验，曾在从发现到商业化的所有发展阶段与新兴生物技术公司合作。在加入Zenas之前，他曾在免疫肿瘤学公司Xilio Therapeutics, Inc.（纳斯达克：XLO）担任首席运营官，从2019年5月至2021年3月，他领导一般和行政、业务发展以及业务运营职能。在加入Xilio Therapeutics之前，他是TESARO的总法律顾问和公司秘书，领导全球法律、合规和政府事务职能，并且从2015年到2019年1月被葛兰素史克收购，是领导团队的关键成员。他此前曾在Cubist Pharmaceuticals Inc.担任首席公司法律顾问，自2012年起直至2015年被默沙东公司收购，并在两家上市公司担任总法律顾问，其中包括Amag制药公司，他还曾担任该公司的首席行政官。他的职业生涯始于Testa，Hurwitz & Thibeault，LLP的公司律师。法默先生在波士顿学院法学院获得法学博士学位，在波士顿大学获得经济学学士学位。
- Joseph L. Farmer has served as President and Chief Operating Officer since February 2022, and served as Chief Biness and Administrative Officer from April 2021 to February 2022. Mr. Farmer is an experienced biopharma executive with over 30 years of transactional and operational experience working with emerging biotechnology companies at all stages of development, from discovery through commercialization. Prior to joining Zenas, he served as Chief Operating Officer at Xilio Therapeutics, Inc. (Nasdaq: XLO), an immuno oncology company, where he led the general and administrative, biness development, and biness operations functions from May 2019 until March 2021. Prior to Xilio Therapeutics, he was the General Counsel and Corporate Secretary at TESARO, a publicly traded biotechnology company, where he led the global legal, compliance and government affairs functions and was a key member of the leadership team from 2015 through its acquisition by GlaxoSmithKline in January 2019. He previoly served as Chief Corporate Counsel at Cubist Pharmaceuticals Inc., from 2012 through its acquisition by Merck & Co. in 2015, and as General Counsel at two publicly traded companies, including AMAG Pharmaceuticals Inc., where he was also the Chief Administrative Officer. He began his career as a corporate attorney at Testa, Hurwitz & Thibeault, LLP. Mr. Farmer received his J.D. from Boston College Law School and his B.A. in economics from Boston University.
- Lisa von Moltke
Lisa von Moltke自2025年3月起担任研发主管兼首席医疗官。她在指导成功的开发项目、领导临床团队以及与跨多个医学领域的监管机构互动方面拥有丰富的经验。在加入Zenas之前，von Moltke博士于2020年4月至2025年3月期间担任赛里斯治疗执行副总裁兼首席医疗官。Previoly，von Moltke博士曾任职于Alkermes, Inc.，在那里她担任过资历不断增加的职务，最终担任高级副总裁兼临床开发主管。在加入阿尔凯默斯之前，von Moltke博士曾在赛诺菲/健赞担任临床药理学副总裁，还曾担任美国首席临床与探索药理科学（CEP）和早期开发，后来担任日本和中国地区的首席CEP。在她职业生涯的早期，von Moltke博士曾担任武田肿瘤公司的转化医学负责人。曾任美国临床药理学院院长，《临床药理》杂志主编。von Moltke博士在莱斯利学院获得了学士学位，并在密歇根州立大学人类医学学院获得了医学博士学位。
Lisa von Moltke has served as Head of Research and Development and Chief Medical Officer since March 2025. She has extensive experience in directing successful development programs, leading clinical teams and interacting with regulatory agencies across multiple areas of medicine. Prior to joining Zenas, Dr. von Moltke served as Executive Vice President and Chief Medical Officer at Seres Therapeutics from April 2020 until March 2025. Previoly, Dr. von Moltke worked for Alkermes, Inc., where she served in roles of increasing seniority, culminating as Senior Vice President and Head of Clinical Development. Prior to joining Alkermes, Dr. von Moltke served as Vice President Clinical Pharmacology at Sanofi/Genzyme Corporation, where she also served as U.S. Head Clinical & Exploratory Pharmacology Sciences (CEP) and Early Development and later as Head CEP for Japan and China regions. Earlier in her career, Dr. von Moltke served as Head, Translational Medicine for the Takeda Oncology Company. She has served as President of the American College of Clinical Pharmacology and as the Editor in Chief of The Jnal of Clinical Pharmacology. Dr. von Moltke earned a B.A. at llesley College and her M.D. from Michigan State University, College of Human Medicine.- Lisa von Moltke自2025年3月起担任研发主管兼首席医疗官。她在指导成功的开发项目、领导临床团队以及与跨多个医学领域的监管机构互动方面拥有丰富的经验。在加入Zenas之前，von Moltke博士于2020年4月至2025年3月期间担任赛里斯治疗执行副总裁兼首席医疗官。Previoly，von Moltke博士曾任职于Alkermes, Inc.，在那里她担任过资历不断增加的职务，最终担任高级副总裁兼临床开发主管。在加入阿尔凯默斯之前，von Moltke博士曾在赛诺菲/健赞担任临床药理学副总裁，还曾担任美国首席临床与探索药理科学（CEP）和早期开发，后来担任日本和中国地区的首席CEP。在她职业生涯的早期，von Moltke博士曾担任武田肿瘤公司的转化医学负责人。曾任美国临床药理学院院长，《临床药理》杂志主编。von Moltke博士在莱斯利学院获得了学士学位，并在密歇根州立大学人类医学学院获得了医学博士学位。
- Lisa von Moltke has served as Head of Research and Development and Chief Medical Officer since March 2025. She has extensive experience in directing successful development programs, leading clinical teams and interacting with regulatory agencies across multiple areas of medicine. Prior to joining Zenas, Dr. von Moltke served as Executive Vice President and Chief Medical Officer at Seres Therapeutics from April 2020 until March 2025. Previoly, Dr. von Moltke worked for Alkermes, Inc., where she served in roles of increasing seniority, culminating as Senior Vice President and Head of Clinical Development. Prior to joining Alkermes, Dr. von Moltke served as Vice President Clinical Pharmacology at Sanofi/Genzyme Corporation, where she also served as U.S. Head Clinical & Exploratory Pharmacology Sciences (CEP) and Early Development and later as Head CEP for Japan and China regions. Earlier in her career, Dr. von Moltke served as Head, Translational Medicine for the Takeda Oncology Company. She has served as President of the American College of Clinical Pharmacology and as the Editor in Chief of The Jnal of Clinical Pharmacology. Dr. von Moltke earned a B.A. at llesley College and her M.D. from Michigan State University, College of Human Medicine.
- Joseph L. Farmer
Joseph L. Farmer，2005年2月成为我们总法律顾问和法律事务副总裁。Farmer先生2008年5月晋升为法律事务高级副总裁，2011年12月成为首席行政官，自2007年他还曾担任我们的秘书长，在加入我们之前，从1997年到2005年Farmer先生是波士顿Testa, Hurwitz和Thibeault有限责任公司（Thibeault, LLP）律师事务所商务实践部的律师，Farmer先生目前担任波士顿管家卡尼医院（Steward Carney Hospital）托管理事会和病人护理咨询委员会成员。他获得波士顿大学（Boston University）经济学学士学位以及波士顿大学法学院（Boston College Law School）法学博士学位。
Joseph L. Farmer has served as Senior Vice President, General Counsel and Secretary since March 2015. From November 2012 until February 2015 Mr. Farmer served as Vice President, Chief Corporate Counsel and Assistant Secretary of Cubist Pharmaceuticals, Inc., prior to its sale to Merck & Co., Inc. Prior to joining Cubist, Mr. Farmer served as Vice President, General Counsel and Secretary of publicly-traded software company Pegasystems Inc. from June until November 2012. From February 2005 until June 2012 Mr. Farmer held management positions with increasing levels of responsibility at AMAG Pharmaceuticals, Inc., a publicly-traded specialty pharmaceutical company, including as its Chief Administrative Officer, General Counsel and Secretary. He received his B.A. in economics from Boston University and his J.D. from Boston College Law School.- Joseph L. Farmer，2005年2月成为我们总法律顾问和法律事务副总裁。Farmer先生2008年5月晋升为法律事务高级副总裁，2011年12月成为首席行政官，自2007年他还曾担任我们的秘书长，在加入我们之前，从1997年到2005年Farmer先生是波士顿Testa, Hurwitz和Thibeault有限责任公司（Thibeault, LLP）律师事务所商务实践部的律师，Farmer先生目前担任波士顿管家卡尼医院（Steward Carney Hospital）托管理事会和病人护理咨询委员会成员。他获得波士顿大学（Boston University）经济学学士学位以及波士顿大学法学院（Boston College Law School）法学博士学位。
- Joseph L. Farmer has served as Senior Vice President, General Counsel and Secretary since March 2015. From November 2012 until February 2015 Mr. Farmer served as Vice President, Chief Corporate Counsel and Assistant Secretary of Cubist Pharmaceuticals, Inc., prior to its sale to Merck & Co., Inc. Prior to joining Cubist, Mr. Farmer served as Vice President, General Counsel and Secretary of publicly-traded software company Pegasystems Inc. from June until November 2012. From February 2005 until June 2012 Mr. Farmer held management positions with increasing levels of responsibility at AMAG Pharmaceuticals, Inc., a publicly-traded specialty pharmaceutical company, including as its Chief Administrative Officer, General Counsel and Secretary. He received his B.A. in economics from Boston University and his J.D. from Boston College Law School.
- Leon Oliver Moulder
Leon Oliver Moulder， Zenas Biopharma, Inc.。创始人，曾担任Zenas Biopharma, Inc.自2023年8月起担任Zenas Biopharma, Inc.的首席执行官。自2020年起担任Zenas Biopharma, Inc.的董事长和董事会成员。自2019年3月以来，他还担任早期生命科学投资基金Tellus BioVentures, LLC（“Tellus”）的管理成员。在成立Tellus之前，他共同创立了TESARO，一家总部位于波士顿的完全整合的肿瘤学生物制药公司（“TESARO”），并从2010年3月起担任首席执行官兼董事，直到2019年1月被GlaxoSmithKline收购。2009年至2010年，他曾担任Abraxis BioScience Inc.（“Abraxis”）的总裁、首席执行官和副董事长。在Abraxis之前，他曾在卫材收购MGI PHARMA后担任北美卫材公司的副董事长，在那里他担任总裁兼首席执行官。此前，他曾担任Eligix Inc.（风险阶段生物技术公司）的创始管理团队成员。他的职业生涯始于临床药剂师，随后在Sanofi S.A.（纳斯达克股票代码：SNY）的前身公司（从Marion Laboratories Inc.开始）工作了17年。Moulder先生是天普大学董事和天普大学日本分校主席。他是芝加哥大学布斯商学院和波尔斯基创业与创新中心的理事会成员。Moulder先生担任Zai Lab Ltd.（纳斯达克股票代码：ZLAB）（“Zai Lab”）、赫尔辛基集团和Trevena Inc.（纳斯达克股票代码：TRVN）以及几家Tellus投资组合公司的董事会成员，包括Dianthus（纳斯达克股票代码：DNTH）。Moulder先生拥有天普大学（Temple University）的药学学位和芝加哥大学布斯商学院（The University of Chicago Booth School of Business）的工商管理硕士学位。于2020年12月担任再鼎医药有限公司提名及企业管治委员会主席。于2026年03月05日调任为再鼎医药有限公司董事。
Leon Oliver Moulder is Founder, has served as Chief Executive Officer since August 2023, and as Chairman and a member of the board of directors since 2020. He has also been the Managing Member of Tell BioVentures, LLC ("Tell"), an early stage life sciences investment fund, since March 2019. Prior to establishing Tell, he cofounded TESARO, Inc., a fully integrated Boston based oncology focused biopharmaceutical company, and served as Chief Executive Officer and director from March 2010 until its acquisition by GlaxoSmithKline in January 2019. Mr. Moulder previoly served as President, Chief Executive Officer and Vice Chairman of Abraxis BioScience Inc. from 2009 to 2010. Prior to Abraxis, he served as Vice Chairman of Eisai Corporation of North America following Eisai's acquisition of MGI PHARMA, where he served as President and Chief Executive Officer. This follod him serving as a member of the founding management team of a venture stage biotech company. Mr. Moulder began his career as a clinical pharmacist follod by a 17 year career at predecessor companies of Sanofi S.A. (Nasdaq: SNY), beginning with Marion Laboratories Inc. Mr. Moulder is a Temple University Trtee and Chair of Temple University Japan. He is a Council Member for both the University of Chicago Booth School of Biness and the Polsky Center for Entrepreneurship and Innovation. Mr. Moulder currently serves on the board of directors of Zai Lab Ltd. (Nasdaq: ZLAB) ("Zai Lab") and for several Tell BioVentures private portfolio companies. Mr. Moulder previoly served on the board of directors of Trevena, Inc. (Nasdaq: TRVN) from 2013 until 2023 and Dianth (Nasdaq: DNTH) from 2019 until 2025. Mr. Moulder received a Pharmacy degree from Temple University and an M.B.A. from The University of Chicago Booth School of Biness.- Leon Oliver Moulder， Zenas Biopharma, Inc.。创始人，曾担任Zenas Biopharma, Inc.自2023年8月起担任Zenas Biopharma, Inc.的首席执行官。自2020年起担任Zenas Biopharma, Inc.的董事长和董事会成员。自2019年3月以来，他还担任早期生命科学投资基金Tellus BioVentures, LLC（“Tellus”）的管理成员。在成立Tellus之前，他共同创立了TESARO，一家总部位于波士顿的完全整合的肿瘤学生物制药公司（“TESARO”），并从2010年3月起担任首席执行官兼董事，直到2019年1月被GlaxoSmithKline收购。2009年至2010年，他曾担任Abraxis BioScience Inc.（“Abraxis”）的总裁、首席执行官和副董事长。在Abraxis之前，他曾在卫材收购MGI PHARMA后担任北美卫材公司的副董事长，在那里他担任总裁兼首席执行官。此前，他曾担任Eligix Inc.（风险阶段生物技术公司）的创始管理团队成员。他的职业生涯始于临床药剂师，随后在Sanofi S.A.（纳斯达克股票代码：SNY）的前身公司（从Marion Laboratories Inc.开始）工作了17年。Moulder先生是天普大学董事和天普大学日本分校主席。他是芝加哥大学布斯商学院和波尔斯基创业与创新中心的理事会成员。Moulder先生担任Zai Lab Ltd.（纳斯达克股票代码：ZLAB）（“Zai Lab”）、赫尔辛基集团和Trevena Inc.（纳斯达克股票代码：TRVN）以及几家Tellus投资组合公司的董事会成员，包括Dianthus（纳斯达克股票代码：DNTH）。Moulder先生拥有天普大学（Temple University）的药学学位和芝加哥大学布斯商学院（The University of Chicago Booth School of Business）的工商管理硕士学位。于2020年12月担任再鼎医药有限公司提名及企业管治委员会主席。于2026年03月05日调任为再鼎医药有限公司董事。
- Leon Oliver Moulder is Founder, has served as Chief Executive Officer since August 2023, and as Chairman and a member of the board of directors since 2020. He has also been the Managing Member of Tell BioVentures, LLC ("Tell"), an early stage life sciences investment fund, since March 2019. Prior to establishing Tell, he cofounded TESARO, Inc., a fully integrated Boston based oncology focused biopharmaceutical company, and served as Chief Executive Officer and director from March 2010 until its acquisition by GlaxoSmithKline in January 2019. Mr. Moulder previoly served as President, Chief Executive Officer and Vice Chairman of Abraxis BioScience Inc. from 2009 to 2010. Prior to Abraxis, he served as Vice Chairman of Eisai Corporation of North America following Eisai's acquisition of MGI PHARMA, where he served as President and Chief Executive Officer. This follod him serving as a member of the founding management team of a venture stage biotech company. Mr. Moulder began his career as a clinical pharmacist follod by a 17 year career at predecessor companies of Sanofi S.A. (Nasdaq: SNY), beginning with Marion Laboratories Inc. Mr. Moulder is a Temple University Trtee and Chair of Temple University Japan. He is a Council Member for both the University of Chicago Booth School of Biness and the Polsky Center for Entrepreneurship and Innovation. Mr. Moulder currently serves on the board of directors of Zai Lab Ltd. (Nasdaq: ZLAB) ("Zai Lab") and for several Tell BioVentures private portfolio companies. Mr. Moulder previoly served on the board of directors of Trevena, Inc. (Nasdaq: TRVN) from 2013 until 2023 and Dianth (Nasdaq: DNTH) from 2019 until 2025. Mr. Moulder received a Pharmacy degree from Temple University and an M.B.A. from The University of Chicago Booth School of Biness.